AddedRisk Factors
There may be and have been changes in legal and regulatory requirements that may materially impact our results of operation.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
We may face new risks as a result of changes in legal and regulatory requirements that may impact our operations and future prospects. For example, the 2025 change in the U.S. federal administration, as well as changes in legal standards, including the reduced level of judicial deference due to administrative agencies following a 2024 Supreme Court decision, may and does introduce regulatory and legal uncertainties that impact our operations. New federal or state laws and regulations may be, and have been, passed or enforced differently than they were before, requiring that we adapt, which we may not be able to do, and expend additional resources to ensure that we are able to comply. New laws and regulations, or the enforcement of the same, may also adversely restrict how we conduct our business. There could also be changes in the FDA’s approval standards that could impact our ability to obtain and maintain product approvals and market our product candidates or that otherwise could impact the competitive market for our products. Legal and regulatory changes may additionally impact how we may market and sell our products and how they are reimbursed. We cannot predict the exact nature of any changes that may take place or whether and how they may impact our business and results of operation.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedRisk Factors
Pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RewordedRisk Factors
In addition, our effective tax rate in a given financial statement period may be materially impacted by a variety of other factors including, but not limited to, changes in the mix and level of earnings, deductible expenses and availability of NOLs changes in the different states and other jurisdictions in which we operate, fluctuations in and deductible expenses and limitations on the valuation allowance on our deferred tax assets, or by changes to existing accounting rules or regulations. use of NOLs resulting from ownership changes.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Violations of laws such as the FDCA, the Social Security Act (including the Anti-Kickback Statute), the Public Health Service Act, the civil and criminal federal False Claims Act, the civil monetary penalty statute, requirements regarding the reporting and repayment of overpayments, other fraud and abuse laws and any regulations promulgated under the authority of the preceding, may result in significant criminal and/or civil sanctions, including jail sentences, fines or criminal fines, imprisonment, civil monetary penalties and damages, exclusion from participation in or federal healthcare programs (including Medicare and Medicaid), suspension and debarment from federal government contracts, and state healthcare or refusal of orders under existing government procurement programs, contracts, pursuant to enforcement actions by DOJ, Medicare, Medicaid, CMS, OIG and other regulatory authorities.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, any such litigation may divert our management's attention from our core business and reduce the resources available for our clinical development, manufacturing and marketing activities, and consequently have a material and adverse effect on our business and prospects, regardless of the outcome.There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent. outcome.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we achieved net income of $197.7 million and $146.9 million for the years ended December 31, 2024 and 2025, respectively, for the year ended December 31, 2024, for the years ended December 31, 2023 and 2022, we incurred a net losses loss of $28.2 million and $65.9 million, respectively. million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Depending on the seriousness of any findings, we or our suppliers may be subject to additional significant enforcement or other actions and events, may need to undertake product recalls, may have a disruption in the supply of commercial or clinical product, or may need to modify or repeat studies, which could have a material impact on our business.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further, there can be no assurance that we will be able to generate the revenue that we believe our products and plasma collection facilities are capable of generating. generating, including but not limited to our current expectations with respect to our yield enhancement production process, which received FDA approval in April 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
As of December 31, 2024, 2025, there were 36,093,118 38,703,218 shares of common stock remaining available for issuance, after giving effect to 11,854,060 9,827,286 shares of our common stock that were subject to outstanding stock options, options and RSUs and warrants as of December 31, 2024 that may be issued by us without stockholder approval, as well as an additional 15,432,277 13,595,000 shares of our common stock reserved for the future issuance of awards under our equity compensation plans.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have employment agreements with each of our executive officers; however, the existence of an employment agreement does not guarantee retention of members of our management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective terms. team.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility Facility, our new real estate in Boca Raton, FL and our plasma collection facilities, are vulnerable to natural disasters (including as a result of climate change), such as interruption by fire, fires, weather related events such as hurricanes, wind and rain, other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure and breakdown, cyberattacks on our operations and information technology systems as well as the systems of our customers, suppliers and related entities, human error, employee issues, global health occurrences such as a pandemic, global and economic uncertainty, war, terrorism, geopolitical conditions and emergencies, product liability claims and events beyond our control.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
As of March 10, 2025, February 20, 2026, most of our 237,615,100 238,159,176 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding warrants, were available for sale in the public market, subject to certain restrictions with respect to sales of our common stock by our affiliates, either pursuant to Rule 144 under the Securities Act, or under effective registration statements.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, our contract fill/finishers and our other third-party vendors may source their materials and supplies globally and are therefore subject to potential tariffs, which could be passed along to us in whole or in part and adversely impact our results of operations, and supply disruptions in the event of fire, weather related events such as hurricanes, wind and rain, international conflicts, strikes, embargoes, trade and sanction requirements and limits, other acts of God or force majeure events or global health occurrences and emergencies.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our senior secured credit facility with Ares Capital Corporation JPMorgan Chase Bank, N.A. and certain of its affiliates (“Ares”) other lenders party thereto (collectively “JPMorgan”) is subject to acceleration in specified circumstances, which may result in Ares JPMorgan taking possession and disposing of any collateral.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Significant estimates Estimates include, among other things, accruals for U.S.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Under the Healthcare Reform Law, payments and transfers of value by pharmaceutical manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to or at the request of covered recipients, such as, but not limited to, U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists and certified registered nurse anesthetists and U.S. teaching hospitals, must be tracked and reported to CMS, and are publicly disclosed.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
In April 2025, the FDA approved our Prior Approval Supplement (the “PAS”) for our innovative yield enhancement production process (the “Yield Enhancement”) benefiting both ASCENIV and BIVIGAM. This PAS approval amends the Biologics License Application (“BLA”) approvals for ASCENIV and BIVIGAM and will continue to be the process by which we will manufacture these products on a go-forward basis. The production methods approved in this PAS have started to result in additional bulk drug yield from the same starting raw material source plasma volumes and the Company believes it should experience meaningful revenue and earnings accretion accelerating further into 2026 and beyond. This innovative process has demonstrated an ability to increase ASCENIV and BIVIGAM production yields by 20% or more from the same starting source plasma volume. Fiscal year 2026 will be our first full year of yield-enhanced production, supporting anticipated sustained margin expansion.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
In July 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted, which includes numerous changes to existing tax law including extending or making permanent certain business provisions initially established under the 2017 Tax Cuts and Jobs Act, which were set to expire. The OBBBA permanently eliminates the requirement to capitalize and amortize U.S.-based research and experimental expenditures, making these expenditures fully deductible in the period incurred. The OBBBA also permanently extends recognition of the accelerated bonus depreciation on qualifying assets in the period acquired. In 2025, these provisions resulted in a reduction of current income tax liabilities and a corresponding reduction to income tax expense.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
In July 2025, we completed the acquisition of real estate in Boca Raton, FL for a total purchase price of $12.6 million. This real estate purchase is intended to allow us to expand our production operations and related activities as well as provide for certain redundancies for ambient and cold-chain storage of raw materials, work in process and finished goods inventory.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, we entered into an agreement for the divestiture of three of our plasma collection centers for an aggregate purchase price of $12.0 million. As of the date of this Annual Report on Form 10-K, two of the plasma collection centers have been sold to the purchaser. The closing of the third center is anticipated to occur in the first quarter of 2026. After the divestiture of all three centers, we will continue to own and operate seven plasma collection centers. In conjunction with the divestiture agreement, we entered into long-term plasma supply agreements with the purchaser of the three plasma collection centers, further diversifying our third-party high-titer plasma supply base. Collectively, these actions reflect a deliberate shift toward a more flexible, capital-efficient supply model and are expected to deliver accretive cost savings beginning in fiscal year 2026, improve capital efficiency, support increased ASCENIV production capacity, and provide durable plasma supply confidence through the late 2030s.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Our provision for income taxes and the determination of our effective tax rate are subject to significant judgment and complexity. We estimate our income tax expense based on enacted tax laws and statutory tax rates in the jurisdictions in which we operate, as well as our interpretation of relevant tax regulations. The effective tax rate includes the impact of various estimates and judgments. Changes in these estimates or in tax laws could significantly affect our effective tax rate and results of operations. Due to the complexity of tax regulations and the potential for differing interpretations, it is reasonably possible that the ultimate resolution of these matters could result in material adjustments to our effective tax rate in future periods.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
(1) Due to Nabi-HB historically representing less than 10% of the Company’s revenue within the ADMA BioManufacturing segment, it has been included under intermediates and other products. The $12.6 million U.S. Medicaid rebate adjustment recorded in 2024 is also included under intermediates and other products.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Income tax expense of $35.7 million for the year ended December 31, 2025 represented an effective tax rate of 19.6%, which differed from the federal statutory rate of 21% primarily due to the excess tax benefits on stock-based compensation and R&D tax credits.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
(1) Due to Nabi-HB historically representing less than 10% of the Company’s revenue within the ADMA BioManufacturing segment, it has been included under intermediates and other products. The $12.6 million U.S. Medicaid rebate adjustment recorded in 2024 is also included under intermediates and other products.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Non-recurring professional fees represent incremental costs associated with a vendor change that we do not expect to incur in future periods and other one-time professional fees.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Non-recurring professional fees represent incremental costs associated with a vendor change that we do not expect to incur in future periods and other one-time professional fees.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Research and development, including studies and development activities relating to SG-001;
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, along with our projected future operating cash flow, will be sufficient to fund our operations, as currently conducted, through the first quarter of 2027 and beyond. Based on current operations and assuming continued market acceptance and utilization of our finished drug products, we do not anticipate the need to raise additional capital at this time. However, should the market for our products or political, economic or inflationary conditions change, we may need to seek additional capital which may not be available due to a variety of potential factors beyond our control (see “Risk Factors” appearing elsewhere in this report).
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedMD&A
In December 2024, we successfully submitted a Prior Approval Supplement (the “PAS”) for potential approval of our innovative yield enhancement production process. Following FDA review of the submission, we anticipate receiving FDA approval by mid-2025, with potential revenue and earnings accretion expected in the second half of the year. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume, potentially driving significant increases to financial targets, if approved.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
Prior to 2024, adjustments to these estimates to reflect actual results or updated expectations have not been material to our overall business. While we have some historical sales and rebate experience from our two primary immunoglobulin products, ASCENIV and BIVIGAM, since their FDA approvals in 2019, our historical experience is not extensive. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate estimates of our future experience, our results could be materially affected. Estimates that are most at risk for material adjustment are those associated with U.S. Medicaid rebates because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally take up to several years or more. These estimates may change from time to time based on changes in utilization, payer and channel mixes. During 2024, we engaged a third-party specialist to assist in the evaluation of our accrual for U.S. Medicaid rebates related to the sale of our immunoglobulin products. As a result of this evaluation, we recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6 million during the year ended December 31, 2024 (see Note 2 to the Consolidated Financial Statements). We considered several qualitative factors when evaluating our rebate accrual, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. There was additional new information that arose during June 2024 that suggested our liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the accrual for U.S. Medicaid rebates in June 2024. Additional changes in estimate assumptions surrounding U.S. Medicaid and other rebate obligations could materially impact our revenues and our results of operations in the future.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
All equity-based payments, including grants of stock options and restricted stock units (“RSUs”), are recognized at their estimated fair value at the date of grant, and compensation expense is recognized on a straight-line basis over the grantee’s requisite vesting period. For the purpose of valuing stock options granted to our employees, directors and executive officers, we use the Black-Scholes option pricing model. We also use the Black-Scholes model when determining additional compensation cost resulting from the modification to previously issued option grants. The Black-Scholes option pricing model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of traded options, and changes in the underlying Black-Scholes assumptions can materially affect the fair value estimate. To determine the risk-free interest rate, we utilize the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with the term of our awards. The expected term of the options granted is in accordance with U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletins 107 and 110 and is based on the average between vesting terms and contractual terms. The expected dividend yield reflects our current and expected future policy for dividends on our common stock. The expected stock price volatility for our stock options was calculated by examining the historical volatility of our common stock since our common stock became publicly traded. We will continue to analyze the expected stock price volatility and expected term assumptions and will adjust our Black-Scholes option pricing assumptions as appropriate. Any changes in the foregoing Black-Scholes assumptions, or our election to utilize an alternative method for valuing stock options granted to employees, directors and executive officers, could potentially impact our stock-based compensation expense and our results of operations.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
Prior to December 31, 2024, we maintained a full valuation allowance against all of our net deferred tax assets, and as a result we have historically not recorded an income tax benefit in the accompanying consolidated financial statements despite continued losses through December 31, 2023. This valuation allowance reflected our assessment of whether it is more likely than not that we would generate sufficient taxable income in the future to be able to utilize our deferred tax assets. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies. We consider all positive and negative evidence to estimate if sufficient future taxable income will be generated to realize our deferred tax assets, and we considered cumulative losses in recent years to be a significant type of negative evidence. As of December 31, 2024, we determined that it is more-likely-than-not that our federal and state deferred tax assets will be realized. As a result, we recorded a release of the valuation allowance associated with these deferred tax assets, which was due in part to achieving three years of cumulative taxable income and projected taxable income that is more than sufficient to realize our federal and state deferred tax assets, and we recorded a deferred income tax benefit in the amount of $84.3 million for the year ended December 31, 2024 (see Note 11 to the consolidated financial statements).
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
Plasma Center Operating Expenses decreased from $17.8 million in the year ended December 31, 2022 to $4.3 million in the year ended December 31, 2023. As a result of our now having ten plasma centers in operation, we were able to more than double the number of liters of plasma collected, with a corresponding reduction in the cost per liter, in 2023 as compared to 2022, coupled with the changes in the market price of normal source plasma and its impact on the net realizable value of our plasma inventory, the amount of plasma center costs we capitalized into inventory increased by approximately $43.2 million in 2023. This amount was largely offset by increases in donor fees of $12.8 million, compensation, benefits and temporary labor of $3.9 million, softgoods and supplies of $5.0 million, donor testing expenses of $4.8 million, depreciation of $0.8 million, software maintenance expense of $0.9 million, janitorial, security and utilities expense of $0.5 million, travel expenses of $0.1 million, advertising expense of $0.2 million, repairs and maintenance expense of $0.2 million and rent of $0.2 million. In addition, our plasma center collections and operating costs were unfavorably impacted by approximately $0.7 million due to the temporary closing of our plasma collection centers attributable to an IT disruption occurring in June 2023, of which all systems have since been fully restored.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
For the year ended December 31, 2024, we had pre-tax income and GAAP net income of $125.7 million and $197.7 million, respectively. We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, along with our projected future operating cash flow, will be sufficient to fund our operations, as currently conducted, through the end of the first quarter of fiscal 2026. However, our current outlook with respect to cash flows and profitability may change based upon several factors, including the continued success of our commercial efforts with respect to the sale of our products and the continued acceptability of our immune globulin products by physicians, patients or payers, and whether or not the assumptions underlying our projected revenues and expenses are correct. If we are unable to maintain positive cash flow throughout fiscal 2025, we may choose to raise additional capital. If we are unable to generate sufficient revenue to maintain positive cash flow throughout fiscal 2025 and elect to raise additional capital, we may decide to do so through public or private equity offerings or debt financings, or we may enter into a corporate collaboration or licensing arrangement. The sale of additional equity securities or debt financings, if convertible, could result in dilution to our stockholders and, in such event, the value and potential future market price of our common stock may decline.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
In connection with the closing of the Ares Credit Facility, we incurred fees and expenses related to the transaction of approximately $2.7 million, including a $1.7 million original issue discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, we are also required to pay Ares an exit fee of $1.7 million upon the earlier of any prepayment date or the Ares Maturity Date, and this obligation has been accrued as a separate liability in our consolidated balance sheet as of December 31, 2024 and 2023 in the amount of $1.3 million and $1.7 million, respectively. As a result, we recognized an aggregate debt discount of $4.4 million as of the Ares Closing Date, and the weighted-average effective interest rate on the Ares Loans as of December 31, 2024 and 2023 was 10.81% and 11.39%, respectively. In connection with the prepayment of the term loan on December 19, 2024, we also paid a pro rata portion of the exit fee in the amount of $0.4 million.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
Events of default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, we will incur an increase in the rate of interest on the Ares Loans of 2% per annum.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
On March 23, 2022 (the “Hayfin Closing Date”), we and all of our subsidiaries entered into the Hayfin Credit Agreement with Hayfin. The Hayfin Credit Agreement, as amended, provided for a senior secured term loan facility in a principal amount of up to $175.0 million, composed of (i) a term loan made on the Hayfin Closing Date in the principal amount of $150.0 million (the “Hayfin Closing Date Loan”), and (ii) a delayed draw term loan in the principal amount of $25.0 million (the “Hayfin Delayed Draw Loan” and, together with the Hayfin Closing Date Loan, the “Hayfin Loans”). The Hayfin Delayed Draw Loan was not drawn prior to our termination of the Hayfin Credit Agreement. The Hayfin Credit Facility had a maturity date of March 23, 2027 (the “Hayfin Maturity Date”), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default (as defined in the Hayfin Credit Agreement).
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
On the Hayfin Closing Date, we used $100.0 million of the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding obligations under our previous senior credit facility with Perceptive (see Note 7 to the Consolidated Financial Statements). We also used $2.0 million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used approximately $1.0 million of the Hayfin Closing Date Loan proceeds to pay certain fees and expenses incurred in connection with this transaction. In addition, a $1.8 million upfront fee payable to Hayfin was paid “in kind” and was added to the outstanding principal balance in accordance with the terms of the Hayfin Credit Agreement.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
Borrowings under the Hayfin Credit Agreement bore interest at the adjusted Term SOFR for either a one-month or three-month tenor, as elected by us, and subject to a floor of 1.25%, plus an applicable margin of 9.5% (the “Applicable Margin”); provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin would increase by an additional 3% per annum. On May 1, 2023 the Hayfin Credit Agreement was amended to reduce the Applicable Margin from 9.5% to 8.5%. On the last day of each calendar month prior to the Ares Closing Date we paid accrued interest to Hayfin. On the Hayfin Closing Date, December 31, 2022 and the Ares Closing Date, the stated interest rate on the Hayfin Loans was 10.75%, approximately 13.7% and approximately 13.9%, respectively. We were also permitted to pay “in kind” a portion of the interest on the Hayfin Loans for each monthly interest period in an amount equal to 2.5% per annum, which was added to the principal amount of the outstanding debt under the Hayfin Credit Facility. From the Hayfin Closing Date through December 31, 2022, $3.0 million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans. For the year ended December 31, 2023, $3.8 million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RemovedMD&A
On the Ares Closing Date, we paid Hayfin the entire outstanding principal amount underlying the Hayfin Loans and any accrued and unpaid interest thereon, as well as an exit fee of 1.0% of the outstanding principal amount being paid. In accordance with the terms of the Hayfin Credit Agreement, we also paid Hayfin the early prepayment fee in the amount equal 7.0% of the prepaid principal amount, or $11.1 million.
Read it in 10-K Mar 18, 2025 at sec.govopen_in_new
RewordedMD&A
The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million liquidity covenant, and also restrict or limit our ability and the ability of our subsidiaries to, among other things and subject to certain exceptions contained in the Ares JPM Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to our or our subsidiaries’ business activities; changes; make certain Investments investments; dispose of certain assets; engage in sale and leaseback transactions or swap agreements; make certain Restricted Payments (each as (as defined in the Ares JPM Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate into any other agreements that have the impact of restricting our ability to make loan repayments under the Ares JPM Credit Agreement. Agreement; or amend certain material documents.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We may prepay The Ares Credit Agreement permitted prepayment of the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days’ prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, Date or (iii) (ii) 1.0% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Years Year Ended December 31, 2025 2024 2023 (in thousands) 2024 2023 2022 Net income (loss) $ 146,930 $ 197,673 $ (28,239) $ (65,904) Loss on extinguishment of debt 3,336 1,243 26,174 6,670 Deferred tax benefit - (84,280) - - Yield enhancement 2,064 - - Stock-based compenstion modifications 757 2,518 - Yield Enhancement expense 1,810 2,064 - IT systems disruption Voluntary Withdrawal and product replacements 6,215 - - Non-recurring professional fees (pre-tax) 1,781 - 2,770 - (a) Adjusted net income (loss) income(b) $ 160,829 $ 119,218 $ 705 $ (59,234)
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
This The increase is primarily attributable due to volume-driven increases in product revenue costs related to higher volume of our increased sales of IG products and plasma plasma, which impacted cost of $39.5 product revenue by $19.7 million and $3.1 $6.7 million, respectively, partially offset by $10.2 million driven by lower volume of intermediates and other, and a reduction in other manufacturing costs, mainly unabsorbed manufacturing expenses, expenses of $5.1 $5.7 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Plasma center operating expenses, which primarily consists consist of compensation, benefits and travel for plasma center management and administrative staff, along with certain initial opening, marketing and start-up costs, were essentially unchanged at staff increased to $4.8 million for the year ended December 31, 2025 as compared to approximately $4.2 million for the year ended December 31, 2024 as compared to approximately $4.3 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
As a result of this transaction, we recorded a loss on the extinguishment of the Hayfin Credit Facility in the amount of $26.2 million in during the year ended December 31, 2023, which is mainly comprised we recorded a total loss on the extinguishment in the amount of the write-off of unamortized debt discount and the prepayment penalty. $26.2 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
However, in the event that we pay paid down an aggregate amount under the revolving facility that is was greater than 50% of revolving facility the $72.5 million commitment of $72.5 million, amount, or $36,250,000, we will were still be required to pay an amount of interest on 50% of this amount, or $36.3 million, the revolving facility that would have been payable had $36,250,000 been outstanding, through the term of Ares Credit Facility. Maturity Date.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Other income, net, for the year ended December 31, 2024 was $1.9 million, as compared to $1.3 We recorded total revenues of $426.5 million for the year ended December 31, 2023. 2024, as compared to $258.2 million for the year ended December 31, 2023, an increase of $168.2 million, or 65%.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by The improvement in cash flow from operations during the year ended December 2024, compared to that for the year ended December 31, 2024 was $118.7 million, as compared 2023, is primarily due to $8.8 million for the year ended December 31, 2023. substantially higher net income.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We anticipate filing In June 2025, we filed our supplemental Biologics License Application (“sBLA”) in mid-2025, with potential FDA approval in the first half of 2026 sBLA for the expansion of ASCENIV’s label to include the pediatric setting for patients who are two years and older. older and we anticipate potential FDA approval in the first half of 2026.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of product revenue was $217.4 million for the year ended December 31, 2025, as compared to $206.9 million for the year ended December 31, 2024, as compared to $169.3 million for the year ended December 31, 2023. an increase of $10.5 million, or 5%.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 (in thousands) 2024 2023 2022 Net cash provided by (used in) operating activities $ 50,396 $ 118,672 $ 8,800 $ (59,508) Net cash used in investing activities (21,891) (8,575) (4,981) (13,911) Net cash (used in) provided by used in financing activities (44,022) (58,302) (38,989) 108,852 Net change in cash and cash equivalents (15,517) 51,795 (35,170) 35,433 Cash and cash equivalents - beginning of year 103,147 51,352 86,522 51,089 Cash and cash equivalents - end of year $ 87,630 $ 103,147 $ 51,352 $ 86,522
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesMD&A
In the future however, future, we may elect to work with the FDA and the immunology and infectious disease community to design an appropriate clinical trial to evaluate the use of ASCENIV in this patient population.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesMD&A
Medicaid rebates, our gross profit for the year ended December 31, 2024 was approximately $207.0 million, representing a gross margin of approximately 50.0%.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new